Four-Drug cocktail aims to control myeloma without transplant

NCT ID NCT07663253

Recruiting now Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd)—in people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The goal is to see how well the regimen controls the disease and what side effects occur in real-world practice. Participants receive the drugs in cycles over about eight months, followed by possible maintenance therapy. The study will measure response rates, including how deeply the cancer is suppressed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isatuximab (Sarclisa) combined with bortezomib, lenalidomide, and dexamethasone
What this could lead to: If successful, this combination could offer a powerful, chemotherapy-free option to control multiple myeloma in people who cannot undergo a stem cell transplant.
What could go wrong: This is an observational study without a comparison group, so results may be less definitive. Side effects from the drug combination can be serious, including infections and blood count changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Affiliated Hospital of Nantong University
RECRUITING

Nantong, Jiangsu, China
Fudan University Affiliated Zhongshan Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200032, China
Harbin Institute of Hematologic Oncology
RECRUITING

Harbin, Heilongjiang, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, China
Jiangsu Provincial People's Hospital
RECRUITING

Nanjing, Jiangsu, China
Peking Union Medical College Hospital
RECRUITING

Beijing, Beijing Municipality, China
Shenzhen People's Hospital
RECRUITING

Shenzhen, Guangdong, China
Sichuan Provincial People's Hospital
RECRUITING

Chengdu, Sichuan, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangxi Medical University
RECRUITING

Naning, Guangxi, 450000, China
The First Affiliated Hospital of Kunming Medical University
RECRUITING

Kunming, Yunnan, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology.
RECRUITING

Wuhan, Hubei, China
Xijing Hospital, Air Force Medical University
RECRUITING

Xi’an, Shanxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.